{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:00:29Z","timestamp":1789693229251,"version":"4.0.1"},"reference-count":28,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>\n                    Pharmacokinetic data regarding ceftaroline fosamil (CPT) penetration into cerebrospinal fluid (CSF) are limited to a rabbit model (15% inflamed) and adult case reports. We describe serum and CSF CPT concentrations in a 21-year-old, 34.8 kg female, medically complex patient presented with a 4-day history of fevers (Tmax 39.2\u00b0C), tachypnea, tachycardia, fatigue, and a 1-week history of pus and blood draining from the ventriculopleural (VPL) shunt. A head CT and an ultrasound of the neck revealed septated complex fluid collection surrounding the shunt. Therapy was initiated with vancomycin and ceftriaxone. Blood and CSF cultures from hospital day (HD) 1 were positive for methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    with a CPT MIC of 0.5 mg\/L and a vancomycin MIC range of 0.5 to 1 mg\/L. On HD 3, CPT was added. On HD 7, simultaneous serum (69.4, 44, and 30.2 mg\/L) and CSF (1.7, 2.3, and 2.3 mg\/L) concentrations were obtained at 0.25, 1.5, and 4.75 hours from the end of an infusion. Based on these concentrations, CPT CSF penetration ratio ranged from 2.4% to 7.6%. After addition of CPT, the blood and CSF cultures remained negative on a regimen of vancomycin plus CPT. On HD 14, a new left-sided VPL shunt was placed. The patient continued on CPT for a period of 7 days after the new VPL shunt placement. This case demonstrated CPT CSF penetration in a range of 2.4% to 7.6%, approximately half of the rabbit model. This allowed for CSF concentrations at least 50% free time &gt; 4 to 6\u00d7 MIC of the dosing interval with a dosing regimen of 600 mg IV every 8 hours in a 34.8 kg chronic patient and resulted in a successful clinical outcome with no identified adverse outcomes.\n                  <\/jats:p>","DOI":"10.5863\/1551-6776-25.4.336","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T16:51:05Z","timestamp":1589820665000},"page":"336-339","source":"Crossref","is-referenced-by-count":5,"title":["Ceftaroline Cerebrospinal Fluid Penetration in the Treatment of a Ventriculopleural Shunt Infection: A Case Report"],"prefix":"10.5863","volume":"25","author":[{"given":"Jeffrey J.","family":"Cies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Enache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"3","key":"i1551-6776-25-4-336-b1","series-title":"Pediatr Crit Care Med","first-page":"346","article-title":"External ventricular drains in pediatric patients","volume":"10","year":"2009","unstructured":"Ngo\n              QN\n            , RangerA, SinghRN, \n          et al. External ventricular drains in pediatric patients. Pediatr Crit Care Med. 2009;10(3):346\u2013351."},{"issue":"2","key":"i1551-6776-25-4-336-b2","series-title":"Clinical article. J Neurosurg Pediatr","first-page":"156","article-title":"Infection rates following initial cerebrospinal fluid shunt placement across pediatric hospitals in the United States","volume":"4","year":"2009","unstructured":"Simon\n              TD\n            , HallM, Riva-CambrinJ, \n          et al. Infection rates following initial cerebrospinal fluid shunt placement across pediatric hospitals in the United States. Clinical article. J Neurosurg Pediatr. 2009;4(2):156\u2013165."},{"issue":"10","key":"i1551-6776-25-4-336-b3","series-title":"Curr Infect Dis Rep","first-page":"427","article-title":"Microbiology and treatment of cerebrospinal fluid shunt infections in children","volume":"16","year":"2014","unstructured":"Adams\n              DJ\n            , RajnikM.\n          Microbiology and treatment of cerebrospinal fluid shunt infections in children. Curr Infect Dis Rep. 2014;16(10):427\u2013428."},{"issue":"5","key":"i1551-6776-25-4-336-b4","series-title":"Pediatr Neurosurg","first-page":"230","article-title":"Long-term follow-up data from the Shunt Design Trial","volume":"33","year":"2000","unstructured":"Kestle\n              J\n            , DrakeJ, MilnerR, \n          et al. Long-term follow-up data from the Shunt Design Trial. Pediatr Neurosurg. 2000;33(5):230\u2013236."},{"issue":"2","key":"i1551-6776-25-4-336-b5","series-title":"J Neurosurg","first-page":"284","article-title":"Lack of benefit of endoscopic ventriculoperitoneal shunt insertion: a multicenter randomized trial","volume":"98","year":"2003","unstructured":"Kestle\n              JR\n            , DrakeJM, CochraneDD, \n          et al. Lack of benefit of endoscopic ventriculoperitoneal shunt insertion: a multicenter randomized trial. J Neurosurg. 2003;98(2):284\u2013290."},{"issue":"5","key":"i1551-6776-25-4-336-b6","series-title":"Neurosurgery","first-page":"459","article-title":"Prospective randomized study of therapy in cerebrospinal fluid shunt infection","volume":"7","year":"1980","unstructured":"James\n              HE\n            , WalshJW, WilsonHD, \n          et al. Prospective randomized study of therapy in cerebrospinal fluid shunt infection. Neurosurgery. 1980;7(5):459\u2013463."},{"issue":"7","key":"i1551-6776-25-4-336-b7","series-title":"Pediatr Infect Dis J","first-page":"632","article-title":"Treatment of cerebrospinal fluid shunt infections: a decision analysis","volume":"21","year":"2002","unstructured":"Schreffler\n              RT\n            , SchrefflerAJ, WittlerRR.\n          Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J. 2002;21(7):632\u2013636."},{"issue":"4","key":"i1551-6776-25-4-336-b8","series-title":"Pharmacotherapy","first-page":"e32","article-title":"Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient","volume":"35","year":"2015","unstructured":"Cies\n              JJ\n            , MooreWS2nd, CalamanS, \n          et al. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient. Pharmacotherapy. 2015;35(4):e32\u2013e36."},{"key":"i1551-6776-25-4-336-b9","series-title":"Ceftaroline [package insert]","year":"2015","unstructured":"Ceftaroline [package insert]. Forest Pharmaceutical IT, Italy; 2015."},{"issue":"2","key":"i1551-6776-25-4-336-b10","series-title":"Am J Health Syst Pharm","first-page":"110","article-title":"Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy","volume":"71","year":"2014","unstructured":"Bucheit\n              J\n            , CollinsR, JoshiP.\n          Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy. Am J Health Syst Pharm. 2014;71(2):110\u2013113."},{"issue":"6","key":"i1551-6776-25-4-336-b11","series-title":"Pediatr Crit Care Med","first-page":"e292","article-title":"Ceftaroline for suspected or confirmed invasive methicillin-resistant Staphylococcus aureus: a pharmacokinetic case series","volume":"19","year":"2018","unstructured":"Cies\n              JJ\n            , MooreWS2nd, EnacheA, \n          et al. Ceftaroline for suspected or confirmed invasive methicillin-resistant Staphylococcus aureus: a pharmacokinetic case series. Pediatr Crit Care Med. 2018;19(6):e292\u2013e299."},{"issue":"5","key":"i1551-6776-25-4-336-b12","series-title":"J Antimicrob Chemother","first-page":"1267","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","year":"2012","unstructured":"Ho\n              TT\n            , CadenaJ, ChildsLM, \n          et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267\u20131270."},{"issue":"3","key":"i1551-6776-25-4-336-b13","series-title":"J Antimicrob Chemother","first-page":"953","article-title":"Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis","volume":"70","year":"2015","unstructured":"Kuriakose\n              SS\n            , RabbatM, GallagherJC.\n          Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother. 2015;70(3):953\u2013954."},{"issue":"5","key":"i1551-6776-25-4-336-b14","series-title":"Int J Antimicrob Agents","first-page":"450","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","year":"2013","unstructured":"Polenakovik\n              HM\n            , PleimanCM.\n          Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42(5):450\u2013455."},{"issue":"4","key":"i1551-6776-25-4-336-b15","series-title":"Antimicrob Agents Chemother","first-page":"2428","article-title":"Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37","volume":"59","year":"2015","unstructured":"Sakoulas\n              G\n            , NonejuieP, KullarR, \n          et al. Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37. Antimicrob Agents Chemother. 2015;59(4):2428\u20132431."},{"issue":"suppl 3","key":"i1551-6776-25-4-336-b16","series-title":"Clin Infect Dis","first-page":"S173","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","year":"2012","unstructured":"File\n              TM\n              Jr\n            , WilcoxMH, SteinGE.\n          Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(suppl 3):S173\u2013S180."},{"issue":"8","key":"i1551-6776-25-4-336-b17","series-title":"Pediatr Infect Dis J","first-page":"837","article-title":"Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011\u20132012)","volume":"33","year":"2014","unstructured":"Sader\n              HS\n            , MendesRE, FarrellDJ, \n          et al. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011\u20132012). Pediatr Infect Dis J. 2014;33(8):837\u2013842."},{"issue":"10","key":"i1551-6776-25-4-336-b18","series-title":"Antimicrob Agents Chemother","first-page":"4653","article-title":"Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant Streptococcus pneumoniae in an experimental rabbit meningitis model","volume":"57","year":"2013","unstructured":"Cottagnoud\n              P\n            , CottagnoudM, AcostaF, \n          et al. Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant Streptococcus pneumoniae in an experimental rabbit meningitis model. Antimicrob Agents Chemother. 2013;57(10):4653\u20134655."},{"issue":"12","key":"i1551-6776-25-4-336-b19","series-title":"Antimicrob Agents Chemother","first-page":"5808","article-title":"Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model","volume":"57","year":"2013","unstructured":"Stucki\n              A\n            , AcostaF, CottagnoudM, \n          et al. Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model. Antimicrob Agents Chemother. 2013;57(12):5808\u20135810."},{"key":"i1551-6776-25-4-336-b20","series-title":"Eur J Clin Pharmacol","first-page":"499","article-title":"Pharmacokinetics of gentamicin in malnourished infants","volume":"21","year":"1982","unstructured":"Bravo\n              ME\n            , ArancibiaA, JarpaS, \n          et al. Pharmacokinetics of gentamicin in malnourished infants. Eur J Clin Pharmacol. 1982;21:499\u2013504."},{"key":"i1551-6776-25-4-336-b21","series-title":"Eur J Clin Pharmacol","first-page":"1025","article-title":"A systematic review of pharmacokinetics studies in children with protein-energy malnutrition","volume":"66","year":"2010","unstructured":"Oshikoya\n              KA\n            , SammonsHM, ChoonaraI.\n          A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 2010;66:1025\u20131035."},{"issue":"3","key":"i1551-6776-25-4-336-b22","series-title":"J Antimicrob Chemother","first-page":"675","article-title":"Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain","volume":"74","year":"2019","unstructured":"Chauzy\n              A\n            , NadjiA, CombesJC, \n          et al. Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain. J Antimicrob Chemother. 2019;74(3):675\u2013681."},{"issue":"2","key":"i1551-6776-25-4-336-b23","series-title":"Surg Infect (Larchmt)","first-page":"169","article-title":"A pharmacokinetic\/pharmacodynamic analysis of ceftaroline prophylaxis in patients with external ventricular drains","volume":"16","year":"2015","unstructured":"Stein\n              GE\n            , YasinF, SmithC, \n          et al. A pharmacokinetic\/pharmacodynamic analysis of ceftaroline prophylaxis in patients with external ventricular drains. Surg Infect (Larchmt). 2015;16(2):169\u2013173."},{"issue":"4","key":"i1551-6776-25-4-336-b24","series-title":"Clin Microbiol Rev","first-page":"858","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","year":"2010","unstructured":"Nau\n              R\n            , SorgelF, EiffertH.\n          Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858\u2013883."},{"key":"i1551-6776-25-4-336-b25","series-title":"Nucleic Acids Res","first-page":"D1091","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","year":"2014","unstructured":"Law\n              V\n            , KnoxC, DjoumbouY, \n          et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42:D1091\u2013D1097."},{"issue":"9","key":"i1551-6776-25-4-336-b26","series-title":"Clin Infect Dis","first-page":"1267","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","year":"2004","unstructured":"Tunkel\n              AR\n            , HartmanBJ, KaplanSL, \n          et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267\u20131284."},{"issue":"2","key":"i1551-6776-25-4-336-b27","series-title":"Antimicrob Agents Chemother","first-page":"885","article-title":"Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae","volume":"58","year":"2014","unstructured":"Van Wart\n              SA\n            , AmbrosePG, RubinoCM, \n          et al. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2014;58(2):885\u2013891."},{"issue":"5","key":"i1551-6776-25-4-336-b28","series-title":"Virulence","first-page":"445","article-title":"Staphylococcus aureus biofilms: properties, regulation, and roles in human disease","volume":"2","year":"2011","unstructured":"Archer\n              NK\n            , MazaitisMJ, CostertonJW, \n          et al. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence. 2011;2(5):445\u2013459."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/4\/article-p336.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/25\/4\/336\/2564368\/1551-6776-25_4_336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/4\/article-p336.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/4\/article-p336.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T20:38:57Z","timestamp":1747341537000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/4\/article-p336.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":28,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-25.4.336","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}